| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.84 [0.71, 1.00] | | < 1 | | 0% | 1 study (1/-) | 97.6 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 0.89 [0.66, 1.21] | | < 1 | | 0% | 1 study (1/-) | 77.3 % | NA | not evaluable | | important | - |
| DCR | 1.19 [0.86, 1.63] | | > 1 | | 0% | 1 study (1/-) | 85.6 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 1.31 [0.86, 2.00] | | > 1 | | 0% | 1 study (1/-) | 89.3 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| TRAE (any grade) | 2.40 [1.76, 3.28] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 2.70 [1.86, 3.92] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 2.00 [0.36, 10.99] | | < 1 | | 0% | 1 study (1/-) | 21.3 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 1.97 [1.40, 2.78] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.27 [1.53, 3.38] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 2.16 [0.96, 4.84] | | < 1 | | 0% | 1 study (1/-) | 3.1 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.84 [1.05, 3.21] | | < 1 | | 0% | 1 study (1/-) | 1.6 % | NA | not evaluable | | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 2.30 [0.99, 5.36] | | < 1 | | 0% | 1 study (1/-) | 2.7 % | NA | not evaluable | | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 1.82 [1.14, 2.91] | | < 1 | | 0% | 1 study (1/-) | 0.6 % | NA | not evaluable | | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.51 [0.48, 13.01] | | < 1 | | 0% | 1 study (1/-) | 13.8 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 6.01 [0.30, 120.38] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.43 [0.54, 3.81] | | < 1 | | 0% | 1 study (1/-) | 23.6 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 8.11 [1.01, 65.20] | | < 1 | | 0% | 1 study (1/-) | 2.5 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 6.14 [1.36, 27.62] | | < 1 | | 0% | 1 study (1/-) | 0.9 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 8.03 [0.42, 152.51] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Pericarditis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 8.03 [0.42, 152.51] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Polymyalgia Rheumatica TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.99 [0.14, 7.10] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 2.51 [0.48, 13.01] | | < 1 | | 0% | 1 study (1/-) | 13.8 % | NA | not evaluable | | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 8.03 [0.42, 152.51] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 1.40 [0.44, 4.45] | | < 1 | | 0% | 1 study (1/-) | 28.5 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Uveitis TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
